WT1 and acute myeloid leukemia: In Conclusion, monitoring measurable residual disease by WT1 expression level either alone (especially in pediatric AML patients without other biological markers) or in combination with other MRD markers may improve the reliability of MRD-based prognostic stratification and thus enable the tailoring of treatment intensity.